AAAAAA

   
Results: 1-23 |
Results: 23
ADVANCING AIDSVAX(TM) TO PHASE-3 - SAFETY, IMMUNOGENICITY, AND PLANS FOR PHASE-3
Authors: FRANCIS DP GREGORY T MCELRATH MJ BELSHE RB GORSE GJ MIGASENA S KITAYAPORN D PITISUTTITHAM P MATTHEWS T SCHWARTZ DH BERMAN PW
Citation: Dp. Francis et al., ADVANCING AIDSVAX(TM) TO PHASE-3 - SAFETY, IMMUNOGENICITY, AND PLANS FOR PHASE-3, AIDS research and human retroviruses, 14, 1998, pp. 325-331
MODULATION OF IMMUNOLOGICAL RESPONSES TO HIV-1(MN) RECOMBINANT GP160 VACCINE BY DOSE AND SCHEDULE OF ADMINISTRATION
Authors: GORSE GJ MCELRATH MJ MATTHEWS TJ HSIEH RH BELSHE RB COREY L FREY SE KENNEDY DJ WALKER MC EIBL MM
Citation: Gj. Gorse et al., MODULATION OF IMMUNOLOGICAL RESPONSES TO HIV-1(MN) RECOMBINANT GP160 VACCINE BY DOSE AND SCHEDULE OF ADMINISTRATION, Vaccine, 16(5), 1998, pp. 493-506
IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS
Authors: CLEMENTSMANN ML WEINHOLD K MATTHEWS TJ GRAHAM BS GORSE GJ KEEFER MC MCELRATH MJ HSIEH RH MESTECKY J ZOLLAPAZNER S MASCOLA J SCHWARTZ D SILICIANO R COREY L WRIGHT PF BELSHE R DOLIN R JACKSON S XU S FAST P WALKER MC STABLEIN D EXCLER JL TARTAGLIA J DULIEGE AM SINANGIL F PAOLETTI E
Citation: Ml. Clementsmann et al., IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS, The Journal of infectious diseases, 177(5), 1998, pp. 1230-1246
ANALYSIS OF INTERCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIONS IN PHASE-I AND PHASE-II TRIALS OF CANDIDATE AIDS VACCINES
Authors: GRAHAM BS MCELRATH MJ CONNOR RI SCHWARTZ DH GORSE GJ KEEFER MC MULLIGAN MJ MATTHEWS TJ WOLINSKY SM MONTEFIORI DC VERMUND SH LAMBERT JS COREY L BELSHE RB DOLIN R WRIGHT PF KORBER BT WOLFF MC FAST PE
Citation: Bs. Graham et al., ANALYSIS OF INTERCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIONS IN PHASE-I AND PHASE-II TRIALS OF CANDIDATE AIDS VACCINES, The Journal of infectious diseases, 177(2), 1998, pp. 310-319
SAFETY PROFILE OF PHASE-I AND PHASE-II PREVENTIVE HIV TYPE-1 ENVELOPEVACCINATION - EXPERIENCE OF THE NIAID AIDS VACCINE EVALUATION GROUP
Authors: KEEFER MC WOLFF M GORSE GJ GRAHAM BS COREY L CLEMENTSMANN ML VERANIKETTER N ERB S SMITH CM BELSHE RB WAGNER LJ MCELRATH MJ SCHWARTZ DH FAST P CHARRON K REYNOLDS MJ ZIMMERMAN E JONES K HARRIS M FREY SE KENNEDY DJ ISRAEL H BERRY C READ B SPITZ T PACATTE T DOLIN R REICHMAN RC LAMBERT J DEMETER L ROBERTS NJ PUGLIESE M BERGER D BURKE J SCOTT T BLACKSTONE E WRIGHT PF BRAEUNER M RYBCZYK GK CRUMBO K BATTLE W CORNELL R OWENS D JENNINGS M HARBISON MA HENSMAN BJ BARR P STABLEIN DM VOSS T PALLAS S LOMAX N KOFF W LAWRENCE D JOHNSTON M SAVARESE B WESCOTT SL
Citation: Mc. Keefer et al., SAFETY PROFILE OF PHASE-I AND PHASE-II PREVENTIVE HIV TYPE-1 ENVELOPEVACCINATION - EXPERIENCE OF THE NIAID AIDS VACCINE EVALUATION GROUP, AIDS research and human retroviruses, 13(14), 1997, pp. 1163-1177
INFLUENZA-VIRUS VACCINATION OF PATIENTS WITH CHRONIC LUNG-DISEASE
Authors: GORSE GJ OTTO EE DAUGHADAY CC NEWMAN FK EICKHOFF CS POWERS DC LUSK RH
Citation: Gj. Gorse et al., INFLUENZA-VIRUS VACCINATION OF PATIENTS WITH CHRONIC LUNG-DISEASE, Chest, 112(5), 1997, pp. 1221-1233
SALIVARY BINDING-ANTIBODIES INDUCED BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GP120 VACCINE
Authors: GORSE GJ YANG EY BELSHE RB BERMAN PW
Citation: Gj. Gorse et al., SALIVARY BINDING-ANTIBODIES INDUCED BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GP120 VACCINE, Clinical and diagnostic laboratory immunology, 3(6), 1996, pp. 769-773
ANTIBODY TO NATIVE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS INDUCED BY IIIB AND MN RECOMBINANT GP120 VACCINES
Authors: GORSE GJ PATEL GB NEWMAN FK BELSHE RB BERMAN PW GREGORY TJ MATTHEWS TJ
Citation: Gj. Gorse et al., ANTIBODY TO NATIVE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS INDUCED BY IIIB AND MN RECOMBINANT GP120 VACCINES, Clinical and diagnostic laboratory immunology, 3(4), 1996, pp. 378-386
INDUCTION OF MUCOSAL ANTIBODIES BY LIVE ATTENUATED AND INACTIVATED INFLUENZA-VIRUS VACCINES IN THE CHRONICALLY ILL ELDERLY
Authors: GORSE GJ OTTO EE POWERS DC CHAMBERS GW EICKHOFF CS NEWMAN FK
Citation: Gj. Gorse et al., INDUCTION OF MUCOSAL ANTIBODIES BY LIVE ATTENUATED AND INACTIVATED INFLUENZA-VIRUS VACCINES IN THE CHRONICALLY ILL ELDERLY, The Journal of infectious diseases, 173(2), 1996, pp. 285-290
A DOSE-RANGING STUDY OF A PROTOTYPE SYNTHETIC HIV-1(MN) V3 BRANCHED PEPTIDE VACCINE
Authors: GORSE GJ KEEFER MC BELSHE RB MATTHEWS TJ FORREST BD HSIEH RH KOFF WC HANSON CV DOLIN R WEINHOLD KJ FREY SE KETTER N FAST PE
Citation: Gj. Gorse et al., A DOSE-RANGING STUDY OF A PROTOTYPE SYNTHETIC HIV-1(MN) V3 BRANCHED PEPTIDE VACCINE, The Journal of infectious diseases, 173(2), 1996, pp. 330-339
IMMUNIZATION WITH ENVELOPE SUBUNIT VACCINE PRODUCTS ELICITS NEUTRALIZING ANTIBODIES AGAINST LABORATORY-ADAPTED BUT NOT PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Authors: MASCOLA JR SNYDER SW WEISLOW OS BELAY SM BELSHE RB SCHWARTZ DH CLEMENTS ML DOLIN R GRAHAM BS GORSE GJ KEEFER MC MCELRATH MJ WALKER MC WAGNER KF MCNEIL JG MCCUTCHAN FE BURKE DS
Citation: Jr. Mascola et al., IMMUNIZATION WITH ENVELOPE SUBUNIT VACCINE PRODUCTS ELICITS NEUTRALIZING ANTIBODIES AGAINST LABORATORY-ADAPTED BUT NOT PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, The Journal of infectious diseases, 173(2), 1996, pp. 340-348
SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL
Authors: GRAHAM BS KEEFER MC MCELRATH MJ GORSE GJ SCHWARTZ DH WEINHOLD K MATTHEWS TJ ESTERLITZ JR SINANGIL F FAST PE WRIGHT PF DOLIN R COREY L BELSHE RB CLEMENTS ML BOLOGNESI DP STABLEIN DM CHERNOFF D DULIEGE AM WALKER CM
Citation: Bs. Graham et al., SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL, Annals of internal medicine, 125(4), 1996, pp. 270
HIV-1 RECOMBINANT GP160 VACCINE-INDUCED ANTIBODIES IN SERUM AND SALIVA
Authors: GORSE GJ ROGERS JH PERRY JE NEWMAN FK FREY SE PATEL GB BELSHE RB SCHWARTZ DH CLEMENTS ML KEEFER M DOLIN R MCELRATH J COREY L GRAHAM BS WRIGHT PF STABLEIN DM MATTHEWS TJ BOLOGNESI D MESTECKY J WALKER MC FAST PE
Citation: Gj. Gorse et al., HIV-1 RECOMBINANT GP160 VACCINE-INDUCED ANTIBODIES IN SERUM AND SALIVA, Vaccine, 13(2), 1995, pp. 209-214
RECOMBINANT GP160 VACCINATION SCHEDULE AND MHC HLA TYPE AS FACTORS INFLUENCING CELLULAR-RESPONSES TO HIV-1 ENVELOPE GLYCOPROTEIN
Authors: GORSE GJ PATEL GB NEWMAN FK MANDAVA M BELSHE RB
Citation: Gj. Gorse et al., RECOMBINANT GP160 VACCINATION SCHEDULE AND MHC HLA TYPE AS FACTORS INFLUENCING CELLULAR-RESPONSES TO HIV-1 ENVELOPE GLYCOPROTEIN, Vaccine, 13(13), 1995, pp. 1170-1179
INCREASED ANTIINFLUENZA-A VIRUS CYTOTOXIC T-CELL ACTIVITY FOLLOWING VACCINATION OF THE CHRONICALLY ILL ELDERLY WITH LIVE ATTENUATED OR INACTIVATED INFLUENZA-VIRUS VACCINE
Authors: GORSE GJ CAMPBELL MJ OTTO EE POWERS DC CHAMBERS GW NEWMAN FK
Citation: Gj. Gorse et al., INCREASED ANTIINFLUENZA-A VIRUS CYTOTOXIC T-CELL ACTIVITY FOLLOWING VACCINATION OF THE CHRONICALLY ILL ELDERLY WITH LIVE ATTENUATED OR INACTIVATED INFLUENZA-VIRUS VACCINE, The Journal of infectious diseases, 172(1), 1995, pp. 1-10
PHASE I II TRIALS OF PREVENTIVE HIV VACCINE CANDIDATES - DOSE AND SCHEDULE - SUMMARY/
Authors: GORSE GJ
Citation: Gj. Gorse, PHASE I II TRIALS OF PREVENTIVE HIV VACCINE CANDIDATES - DOSE AND SCHEDULE - SUMMARY/, AIDS research and human retroviruses, 10, 1994, pp. 190000141-190000143
STUDIES OF HIGH-DOSES OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GLYCOPROTEIN-160 CANDIDATE VACCINE IN HIV TYPE-1-SERONEGATIVE HUMANS
Authors: KEEFER MC GRAHAM BS BELSHE RB SCHWARTZ D COREY L BOLOGNESI DP STABLEIN DM MONTEFIORI DC MCELRATH MJ CLEMENTS ML GORSE GJ WRIGHT PF MATTHEWS TJ SMITH GE LAWRENCE D DOLIN R
Citation: Mc. Keefer et al., STUDIES OF HIGH-DOSES OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GLYCOPROTEIN-160 CANDIDATE VACCINE IN HIV TYPE-1-SERONEGATIVE HUMANS, AIDS research and human retroviruses, 10(12), 1994, pp. 1713-1723
VACCINE-INDUCED ANTIBODIES TO NATIVE AND RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS
Authors: GORSE GJ FREY SE PATEL G NEWMAN FK BELSHE RB SCHWARTZ D CLEMENTS ML KEEFER M ROBERTS N DOLIN R MCELRATH J COREY L GRAHAM BS WRIGHT P MATTHEWS T BOLOGNESI D WALKER MC FAST P FERNIE BF
Citation: Gj. Gorse et al., VACCINE-INDUCED ANTIBODIES TO NATIVE AND RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS, Vaccine, 12(10), 1994, pp. 912-918
NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1
Authors: BELSHE RB GRAHAM BS KEEFER MC GORSE GJ WRIGHT P DOLIN R MATTHEWS T WEINHOLD K BOLOGNESI DP SPOSTO R STABLEIN DM TWADDELL T BERMAN PW GREGORY T IZU AE WALKER MC FAST P
Citation: Rb. Belshe et al., NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1, JAMA, the journal of the American Medical Association, 272(6), 1994, pp. 475-480
DETERMINANTS OF ANTIBODY-RESPONSE AFTER RECOMBINANT GP160 BOOSTING INVACCINIA-NAIVE VOLUNTEERS PRIMED WITH GP160-RECOMBINANT VACCINIA VIRUS
Authors: GRAHAM BS GORSE GJ SCHWARTZ DH KEEFER MC MCELRATH MJ MATTHEWS TJ WRIGHT PF BELSHE RB CLEMENTS ML DOLIN R COREY L BOLOGNESI DP STABLEIN DM ESTERLITZ JR HU SL SMITH GE
Citation: Bs. Graham et al., DETERMINANTS OF ANTIBODY-RESPONSE AFTER RECOMBINANT GP160 BOOSTING INVACCINIA-NAIVE VOLUNTEERS PRIMED WITH GP160-RECOMBINANT VACCINIA VIRUS, The Journal of infectious diseases, 170(4), 1994, pp. 782-786
HIV-1 RECOMBINANT GP160 VACCINE GIVEN IN ACCELERATED DOSE SCHEDULES
Authors: GORSE GJ SCHWARTZ DH GRAHAM BS MATTHEWS TJ STABLEIN DM FREY SE BELSHE RB CLEMENTS ML WRIGHT PF EIBL M FAST PE
Citation: Gj. Gorse et al., HIV-1 RECOMBINANT GP160 VACCINE GIVEN IN ACCELERATED DOSE SCHEDULES, Clinical and experimental immunology, 98(2), 1994, pp. 178-184
INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS
Authors: BELSHE RB CLEMENTS ML KEEFER MC GRAHAM BS COREY L SPOSTO R WESCOTT S LAWRENCE D GORSE GJ KENNEDY D FREY S LAMBERT J SCHWARTZ D DOLIN R ROBERTS N MCELRATH J COOMBS J WRIGHT P KARZON D FAST P WALKER MC MESTECKY J JACKSON S STABLEIN D WOLFF M
Citation: Rb. Belshe et al., INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS, Annals of internal medicine, 121(8), 1994, pp. 584
SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION
Authors: BELSHE RB CLEMENTS ML DOLIN R GRAHAM BS MCELRATH J GORSE GJ SCHWARTZ D KEEFER MC WRIGHT P COREY L BOLOGNESI DP MATTHEWS TJ STABLEIN DM OBRIEN FS EIBL M DORNER F KOFF W
Citation: Rb. Belshe et al., SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION, The Journal of infectious diseases, 168(6), 1993, pp. 1387-1395
Risultati: 1-23 |